{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:54:55Z","timestamp":1772510095107,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins,France","award":["PHRCI-2021-86"],"award-info":[{"award-number":["PHRCI-2021-86"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With more than 15,000 new cases \/year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1\/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers. If in metastatic disease, the follow-up of circulating tumor DNA (ctDNA) has been demonstrated, its interest in adjuvant setting remains to be precised, especially because of a lower detection rate. Further, the definition of a molecular response could prove useful to personalized treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PERCIMEL is an open prospective multicentric study executed through collaboration of the Institut de Canc\u00e9rologie de Lorraine (non-profit comprehensive cancer center) and 6 French university and community hospitals. A total of 165 patients with resected stage III and IV melanoma, eligible to adjuvant imunotherapy or anti-BRAF\/MEK kinase inhibitors will be included. The primary endpoint is the presence of ctDNA, 2 to 3\u00a0weeks after surgery, defined as mutated ctDNA copy number calculated as the allelic fraction of a clonal mutation relative to total ctDNA. Secondary endpoints are recurrence-free survival, distant metastasis-free survival and specific survival. We will follow ctDNA along treatment, quantitatively through ctDNA mutated copy number variation, qualitatively through the presence of cfDNA and its clonal evolution. Relative and absolute variations of ctDNA during follow-up will be also analyzed.<\/jats:p>\n                <jats:p>PERCIMEL study aims at provide scientific evidence that ctDNA quantitative and qualitative variations can be used to predict the recurrence of patients with melanoma treated with adjuvant immunotherapy or kinase inhibitors, thus defining the notion of molecular recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-11029-4","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T08:03:12Z","timestamp":1686902592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Personalized follow-up of circulating DNA in resected stage III\/IV melanoma: PERCIMEL multicentric prospective study protocol"],"prefix":"10.1186","volume":"23","author":[{"given":"Lionnel","family":"Geoffrois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Harl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Sahki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Sikanja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Jeudy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charl\u00e9e","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Huin-Schohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"19","key":"11029_CR1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebb\u00e9 C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA, CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"19","key":"11029_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"key":"11029_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"issue":"33","key":"11029_CR4","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG\/KEYNOTE-054 Trial. J Clin Oncol. 2020;38(33):3925\u201336.","journal-title":"J Clin Oncol"},{"issue":"11","key":"11029_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, M\u00e1rquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377.","journal-title":"Lancet Oncol"},{"issue":"3","key":"11029_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358\u201372.","journal-title":"Lancet Oncol"},{"issue":"9","key":"11029_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"11029_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.arcmed.2018.10.007","volume":"49","author":"C Franczak","year":"2018","unstructured":"Franczak C, Filhine-Tressarieu P, Bros\u00e9us J, Gilson P, Merlin JL, Harl\u00e9 A. Clinical Interest of Circulating Tumor DNA in Oncology. Arch Med Res. 2018;49(5):297\u2013305.","journal-title":"Arch Med Res"},{"issue":"22","key":"11029_CR9","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","volume":"22","author":"L Xi","year":"2016","unstructured":"Xi L, Pham THT, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. Clin Cancer Res. 2016;22(22):5480\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11029_CR10","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1038\/s41598-019-53917-5","volume":"9","author":"RB Forthun","year":"2019","unstructured":"Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Naml\u00f8s HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Sci Rep. 2019;9(1):17471.","journal-title":"Sci Rep"},{"issue":"5","key":"11029_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with antieprogrammed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717\u201321.","journal-title":"JAMA Oncol"},{"issue":"39","key":"11029_CR12","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget"},{"issue":"1","key":"11029_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s12885-018-4637-6","volume":"18","author":"AC McEvoy","year":"2018","unstructured":"McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, Khattak MA, Meniawy TM, Millward M, Ziman M, Gray ES. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018;18(1):726.","journal-title":"BMC Cancer"},{"issue":"1","key":"11029_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, Del Marmol V, Heimann P, Neyns B. Undetectable circulating tumor DNA (ctDNA) levels correlate with favourable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.","journal-title":"J Transl Med."},{"key":"11029_CR15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/ijc.22598","volume":"120","author":"M Daniotti","year":"2007","unstructured":"Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007;120:2439\u201344.","journal-title":"Int J Cancer"},{"issue":"3","key":"11029_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda MM, Wiggins JM, Corless BC, Long GV, Flaherty KT, Schadendorf D, Nathan PD, Robert C, Ribas A, Davies MA, Grob JJ, Gasal E, Squires M, Marker M, Garrett J, Brase JC, Polsky D. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021;22(3):370\u201380.","journal-title":"Lancet Oncol"},{"key":"11029_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, Follo M, Philipp U, Hussung S, Pfeifer D, Mix M, Duyster J, Fritsch R, von Bubnoff D, Meiss F, von Bubnoff N. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precis Oncol. 2020;4:20\u201331.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"11029_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol. 2018;29(2):490\u20136.","journal-title":"Ann Oncol"},{"issue":"5","key":"11029_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdz075","volume":"30","author":"JH Lee","year":"2019","unstructured":"Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Ann Oncol. 2019;30(5):815\u201322.","journal-title":"Ann Oncol"},{"issue":"5","key":"11029_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804\u201314.","journal-title":"Ann Oncol"},{"key":"11029_CR21","first-page":"PO.18.00229","volume":"3","author":"R V\u00e1raljai","year":"2019","unstructured":"V\u00e1raljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, Griewank K, Placke JM, Horn PA, von Neuhoff N, Shannan B, Chauvistr\u00e9 H, Vogel FCE, Horn S, Becker JC, Newton-Bishop J, Stang A, Neyns B, Weide B, Schadendorf D, Roesch A. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precis Oncol. 2019;3:PO.18.00229.","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"11029_CR22","doi-asserted-by":"publisher","first-page":"100357","DOI":"10.1016\/j.esmoop.2021.100357","volume":"7","author":"MA Gouda","year":"2021","unstructured":"Gouda MA, Polivka J, Huang HJ, Treskova I, Pivovarcikova K, Fikrle T, Woznica V, Dustin DJ, Call SG, Meric-Bernstam F, Pesta M, Janku F. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. ESMO Open. 2021;7(1):100357.","journal-title":"ESMO Open"},{"issue":"suppl7","key":"11029_CR23","doi-asserted-by":"publisher","first-page":"S904","DOI":"10.1016\/j.annonc.2022.07.914","volume":"33","author":"GV Long","year":"2022","unstructured":"Long GV, Desai K, Tang T, Weber J, Dolfi S, Ritchings C, Huang SP, Bolisetty M, Sausen M, Del Vecchio M, Larkin J, Baden J, Balli D, Chang H, Loffredo J, Zhang N, Wind-Rotolo M, Tenney DJ. Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). Ann Oncol. 2022;33(suppl7):S904.","journal-title":"Ann Oncol"},{"issue":"4","key":"11029_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","volume":"19","author":"M Maio","year":"2018","unstructured":"Maio M, Lewis K, Demidov L, Mandal\u00e0 M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D, BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4):510\u201320.","journal-title":"Lancet Oncol."},{"issue":"10","key":"11029_CR25","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3390\/cancers12102914","volume":"12","author":"A Sacco","year":"2020","unstructured":"Sacco A, Forgione L, Carotenuto M, Luca A, Ascierto PA, Botti G, Normanno N. Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. Cancers (Basel). 2020;12(10):2914.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11029-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T08:05:56Z","timestamp":1686902756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11029-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11029"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11029-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"21 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>Regulatory requirements<\/b>The study will be performed in compliance with:\u2022 The ethical principles as outlined in the latest version of the Declaration of Helsinki;\u2022 Good Clinical Practice, as defined in the version dated 24 November 2005 from the International Conference on Harmonization (ICH-E6);\u2022 French National legislation on privacy of personal data (\u201cInformatique et Libert\u00e9s\u201d law number 78\u201317 dated 6 January 1978, modified by law number 2004\u2013801 dated 6 August 2004) relating to the protection of privacy in the management of personal data;\u2022 French Bioethics law number 2004\u2013800 dated 6 August 2004;\u2022 French Decree number 2016\u20131537 dated 16 November 2016 relating to research involving human subjects;\u2022 French decree dated 7 May 2017 listing the types of research mentioned in paragraph 2 of article L. 1121\u20131 of the code of public health;\u2022 French decree dated 9 May 2017 modifying certain regulatory dispositions relating to research involving human subjects.<b>Ethics committee, competent authority, CNIL (national data privacy commission)<\/b>Prior to initiating any research involving human subjects, the sponsor is required to submit the project for approval to an Ethics Committee with competence for the location in which the lead investigator practices, and for information to the French health products safety agency (ANSM). The sponsor will submit a request for approval to the competent authority for the conduct of an interventional research study with minimal risks and constraints.Requests for substantial modifications to the initial protocol will also be sent by the sponsor to the Ethics Committee for approval, and to the competent authority for information.This study is performed in compliance with the reference methodology MR-001 of the CNIL (national data privacy commission). The promoter, Institut de Cancerologie de Lorraine, has declared to be in conformity with the MR-001 methodology for the treatment of patients\u2019 personal data for the purposes of biomedical research (declaration number 2203858 dated 24 July 2018).Patient information and informed consent from the patient must be handled in accordance with the French regulation. Prior to the participation of a patient in the trial, this patient will be informed both verbally and in writing about the objectives of the trial, its methods, anticipated benefits and potential risks and the discomfort to which they may be exposed. The informed consent form for study and ancillaries studies, must be personally dated and signed by the patient and investigator.The present protocol was approved by the Ethics Committee (Comit\u00e9 de Protection des Personnes Sud Est V) on 13\/12\/2022 under the reference number SI RIPH 2G: 22.04019.000105, and is registered on ClinicalTrials.gov with the number NCT04866680, and in ID-RCB with the number 2022-A01904-39.The first patient was included on February 6th, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JLM received honoraria for consulting and financial supports for participation to meetings by Novartis, Bristol Myers Squibb, MSD, Pierre Fabre, Roche.JLM and AHa received financial research grants from Novartis.AHa received honoraria for consulting and financial supports for participation to meetings by Biocartis, BioRad, BMS, MSD, Novartis, Pierre Fabre, Roche, Sophia Genetics.GJ received honoria for consulting and financial supports for participation to mmeetings by Novartis, BMS, MSD, Pierre Fabre.FGB received honoraria for consulting and financial supports for participation to meetings by Novartis, Bristol Myers Squibb, MSD, Pierre Fabre, Sun Pharma.CM received honoraria for consulting and financial supports for participation to meetings by BMS, Novartis, Pierre Fabre,.CN received honoraria for consulting and financial supports for participation to meetings by Novartis, Bristol Myers Squibb, MSD, Pierre Fabre.LM received honoraria for consulting and financial supports for participation to meetings by Novartis, Bristol Myers Squibb, MSD, Merck, Pierre Fabre.AHe received honoraria for consulting by Novartis, Pierre Fabre, MSD.All other authors declared that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"554"}}